Core Insights - Aptorum Group Limited, DiamiR Biosciences Corp., and Instant NanoBiosensors Co., Ltd. have announced a collaboration to validate INB's automated APOE testing platform for clinical use in DiamiR's laboratory [1][4] Group 1: Collaboration and Testing - DiamiR will compare INB's automated G8 Genotyping Analyzer for APOE testing with its New York State approved APOE test to evaluate performance and suitability for Alzheimer's disease testing [3] - The collaboration aims to introduce an automated testing solution for Alzheimer's disease risk assessment into clinical practice, enhancing testing capabilities and laboratory throughput [4] Group 2: APOE Testing Significance - The APOE gene is the strongest known genetic risk factor for late-onset Alzheimer's disease, with carriers of one copy having a 2-4 times higher risk and those with two copies having an 8-12 times higher risk compared to non-carriers [2][5] - Approximately 15% to 25% of the population has at least one copy of the APOE ε4 allele, and 2% to 5% carry two copies, making APOE testing a crucial tool in clinical management [5] Group 3: Company Backgrounds - DiamiR Biosciences focuses on developing minimally invasive tests for early detection and monitoring of brain health conditions, supported by over 50 issued patents worldwide [6] - Aptorum Group is a clinical stage biopharmaceutical company dedicated to discovering and commercializing therapeutic assets for diseases with unmet medical needs, particularly in oncology and infectious diseases [9] - Instant NanoBiosensors develops advanced biosensor platforms to improve biomedical research and diagnostic workflows, aiming for cost-effective and reliable technologies [10]